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Abstract
Unknown primary tumors (UPTs) represent an entity of
great clinical and biological interest, whose origin
cannot be determined even after medical workup. To
better understand their pathogenesis by outlining their
genetic composition, 20 UPTs were investigated by G-
banding, supplemented with Fluorescence In Situ
Hybridization and Comparative Genomic Hybridization
analyses. The data obtained were sufficient to reach a
diagnosis in five cases— four lymphomas and one
Ewing sarcoma— demonstrating that in a subset of
UPTs, cytogenetics can be an adjunct for differential
diagnosis. In the remaining 15 UPTs, an aggressive
cytogenetic pattern was revealed. The most frequently
rearranged chromosome regions were 1q21, 3p13,
6q15–23, 7q22, 11p12–5, and 11q14–24, pinpointing
gene loci probably associated with the peculiar patho-
genesis of UPTs. The preferential involvement of 4q31,
6q15, 10q25, and 13q22 in adenocarcinomas (whereas
11q22 is involved in the rest of the carcinomas) — in
addition to the marked divergence in the mean aver-
age of chromosomal changes, 16 and 3, respectively —
demonstrates genotypic differences between the two
histologic subgroups. Furthermore, the significantly
shorter survival in cases displaying massive chromo-
some changes compared with those having a few
changes indicates that the cytogenetic pattern might
be used as a tool to assess prognosis in UPTs, even
without the detection of their primary site.
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Introduction
Unknown primary tumors (UPTs), manifested by clinical
signs and symptoms of a tumor whose type and origin cannot
be ascertained, are an entity of great clinical and biological
interest. It represents about 5% to 10% of all solid tumors [1–
5]. The clinical features of patients with UPT are heteroge-
neous and their prognosis is very difficult to assess. Hence,
there is no basis for a uniform treatment course or a rational
individualized treatment strategy without any knowledge of
the tumor origin and its biological behavior. In spite of the
varying origin, however, UPTs appear to have common
biologic characteristics, including their potential to become
malignant early in tumor development [2,6 ]. It is, therefore,
clear that there is a need to establish tools that contribute to a
better understanding of the metastatic process, to trace their
origin, and to distinguish subgroups with a better prognosis or
response to the therapy [7–10].
In the last decade, genetic analysis has provided a vast
amount of valuable novel information about the pathogenesis
of various tumor entities. The monitoring of genetic changes
is becoming a supplement for the classification of several
human neoplasms, contributing to differential diagnosis and
assessment for each individual patient [11,12]. However,
very few studies utilizing genetic techniques have focused on
the genetic characterization of UPTs. The low frequency of
p53 mutations that has been reported in two UPT series
[13,14] comprises the only known genetic feature for this
type of cancer. As for determining the tumor origin, the only
genetic aberration that has been identified in a subset of
UPTs and has repeatedly been used to differentiate germ cell
tumors from malignancies of other histogenesis is i(12p)
[15–20]. Using chromosome analysis, the diagnosis of
primary renal carcinoma, initially presented as metastasis
of unknown origin, has been achieved in a single published
case [21], whereas in a Comparative Genomic Hybridization
(CGH) study on brain metastases of solid tumors [22], the
DNA copy number changes of a total of three metastases of
unknown primary have been reported. Thus, up to the
present, the genetic characteristics of UPTs remain largely
unknown, although theoretically they might influence, if not
determine, the phenotypic peculiarity of these tumors.
To investigate the genetic profile of a series of UPTs, we
have chosen to start from cytogenetic analysis, a methodo-
logical approach that, although laborious, remains the only
one capable of detecting genomewide aberrations, including
both balanced and unbalanced chromosome changes in
euchromatic and heterochromatic regions, as well as cell -
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to-cell variation in a tumor population. In cases where tumor
materials were available after G-banding was completed,
CGH and interphase Fluorescence In Situ Hybridization
(FISH) were performed to complement classical cytoge-
netics by including data from nondividing tumor cell
populations.
Materials and Methods
Tumor Samples and Patients’ Clinicopathologic Features
Tumor specimens were obtained from surgical resections
of 34 tumors suspected of being UPTs, treated at the
Department of Orthopedics of ‘‘Saint Savas’’ Oncological
Table 1. Clinical and Histopathologic Data of 20 Patients With Tumors of Unknown Origin.
Case Number / Laboratory Code Sex /Age Site of metastasis* Histologic Type Survival (months )
1 / 97216 M/46 Bone Adenocarcinoma 3
2 / 97243 M/65 Pubic Carcinoma
3 / 98020 M/70 Femur Carcinoma 24
4 / 98302 M/72 Pelvic bone Adenocarcinoma 2
5 / 99231 M/35 Clavicle Malignant neoplasm
6 / 00012 M/59 Subcutaneous metastasis Adenocarcinoma 6
7 / 00023 F / – Subcutaneous metastasis Adenocarcinoma
8 / 00027 F / 69 Multiple metastases ( omentum) Adenocarcinoma
9 / 00032 M/65 Femur Carcinoma 15
10 / 00082 M/ – Tibial bone Malignant neoplasm
11 / 00106 M/72 Femur Malignant neoplasm
12 / 00115 M/ – Humerus Adenocarcinoma 12
13 / 00136 M/16 Bone Malignant neoplasm
14 / 00142 M/60 Femur Carcinoma 25
15 / 00154 M/70 Multiple metastases ( peritoneum ) Malignant neoplasm 1
16 / 00184 M/ – Bone Malignant neoplasm
17 / 00188 F / 32 Femur Malignant neoplasm
18 / 01035 M/59 Tibial bone Malignant neoplasm 2
19 / 01047 M/53 Vertebra Carcinoma 18
20 / 01088 M/36 Pelvic bone Malignant neoplasm 10 alive
*In cases with multiple metastases, the site from which the examined sample was taken is indicated in parentheses.
Figure 1. A graphic illustration of the breakpoint distribution along the autosomal chromosomes ( from 1p36 to 22q13 ) identified by G-banding analysis in the 15
tumors, in which a final diagnosis was not reached. In the total series of tumors (black, thick line ), the highest frequency was found at 6q15, followed by 3p13 and
7q22. When, however, the tumors were divided according to their histologic type, the highest frequency was observed at 6q15, followed by 4q31, 10q15, and 13q22
in adenocarcinomas (black, thin line ), whereas 11q22 showed the highest frequency in carcinomas (white line ).
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Hospital of Athens, between 1997 and 2001. None of the
patients had any history of a previous malignant disease, or
received any treatment before the initial tumor biopsy. The
tumor samples were transferred for cytogenetic analysis to
the Department of Genetics of the ‘‘Saint Savas’’ Oncological
Hospital of Athens, immediately after surgery. A tumor
aliquot was kept at 808C until DNA extraction. Adjacent
samples were sent for histopathologic examination. The
clinical and pathologic evaluations, including history, phys-
ical examination, and basic laboratory tests, revealed either
a metastatic cancer from a known primary site, or other types
of benign and malignant neoplasms in 14 tumors. Those
tumors have been excluded from the present study. Of the
remaining 20 tumors, the patients’ clinical features and
histopathologic characteristics are presented in Table 1.
Seventeen patients were male and three were female. The
mean age of the patients was 59.2 years old. The histologic
type was poorly differentiated adenocarcinoma in six cases,
carcinoma in five cases, and malignant neoplasm in the
remaining nine cases. Only 1 of 11 patients, for whom
survival information was available, is still alive, whereas the
other 10 died within a period of 1 to 25 months after the initial
diagnosis.
Short -Term Cultures
The samples were processed for cytogenetic analysis as
previously described [23,24]. In brief, the tumor tissue was
washed, mechanically minced, enzymatically disaggregated,
and then cultured short term in plastic flasks with Dulbecco’s
MEM/F12 (1:1) medium, supplemented with 10% fetal
bovine serum, L-glutamine, penicillin, and streptomycin.
After 3 to 10 days, the cells were arrested at metaphase with
Colcemid and then harvested as previously described [24].
Metaphase Cytogenetics by G-Banding Analysis
Chromosome slides were prepared from each harvesting
and the chromosomes were G-banded with Wright’s stain.
When enough material was available for the completion of
G-banding analysis, cell suspensions were kept in fixative
and stored at 208C for the subsequent interphase
investigation. In the cytogenetic analysis, the clonality criteria
and the description of the karyotypic abnormalities followed
the recommendations of ISCN (1995) [25]. The chromoso-
mal breakpoints and imbalances were illustrated (Figures 1
and 2) based on the findings only in cases in which a final
diagnosis was not reached after the genetic investigation. To
assess the distribution of chromosomal breakpoints and
imbalances, the involvement of each chromosome band or
area in aberrations was indicated once per tumor sample,
even when the same region was involved in more than one
aberration.
Interphase Cytogenetics by FISH Analysis
Interphase FISH was performed in five cases (Table 2) in
which there was a diagnostic dilemma among lymphoma,
primitive ectodermal tumors (PNETs), and carcinoma after
Figure 2. A histogram illustrating the imbalances identified by the combination approach (G -banding and CGH), along the autosomal chromosomes ( from 1p36 to
22q13 ) in the 15 tumors, in which a final diagnosis was not reached. Gains appear as positive values while losses appear as negative values. The most frequent
gains were those of 1q21, 7q22, and 11p12–15, whereas the most frequent losses were those of 6q21–23 and 11q14–24.
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the histopathologic examination. Slides for interphase cyto-
genetics were prepared from cell suspensions stored at
208C until use. The areas of the proper cell density and of
the best quality were chosen in each of the preparations using
a phase contrast microscope. Two locus-specific breakapart
probes were used for FISH analysis — one for IgH, which
hybridizes to 14q32, and another forALK, which hybridizes to
2p23. Both probes were dual -colored, and directly labeled
with Spectrum Green and Spectrum Red (VYSIS, Downers
Grove, IL). Hybridization with each of the probes was
performed separately in different slides as prescribed by
the manufacturer (VYSIS). Preparations of normal lympho-
cytes from healthy donors were used as controls for each
hybridization procedure. A total of 60 to 100 nuclei were
examined from each tumor sample by three independent
investigators (D.P., H.T., and G.B. ). Only cases that showed
breakapart signals in more than 20% of the examined nuclei
were considered to have each rearrangement.
CGH
CGH analysis was performed according to Kallionemi
et al. [26]. Briefly, tumor and reference DNA were extracted
using standard methods. Tumor DNA was labeled by nick
translation with spectrum green dUTP (VYSIS). Spectrum
red directly labeled normal DNA was used as reference
(VYSIS). Labeled tumor and reference DNA (400 ng each)
were mixed together with 10 g of CotI DNA (VYSIS),
precipitated in ethanol, dried, and dissolved in a hybridization
buffer (VYSIS). The resulting mixture was denatured at 758C
for 5 minutes and applied to normal metaphase slides
obtained from lymphocyte cultures from healthy male
donors, or applied to commercially available slides (VYSIS).
The hybridization was performed at 378C for 3 days, after
which the slides were washed, air -dried, and mounted in an
antifade solution with DAPI (VYSIS). An analysis was
performed using a Zeiss Axioplan fluorescence microscope
and an ISIS image analysis system (MetaSystems, Altlus-
sheim, Germany). Data obtained from at least 10 metaphase
cells were used and the average ratio profiles were
calculated to suppress random changes. Losses of DNA
sequences were defined by ratios less than 0.80, and gains
were defined by ratios higher than 1.25. In the subset of
tumors with a cytogenetically defined modal chromosome
number at the near- triploid range, an additional setting of the
upper and lower thresholds at 1.17 and 0.83, respectively,
was also used to pick out more gains and losses. The
deviations of the average ratio profiles from the normal value
of 1.0 were tested for significance by Student’s t - test by
applying a 99% confidence interval. Thus, in all cases, DNA
gains or losses were first scored as fixed values, detected
out of the upper or lower threshold values. Then, by the
statistical procedure described above, DNA gains or losses
were scored only if the ratio profile, together with its 99%
interval, was reached. A negative control normal versus
normal and a positive control (a highly abnormal cell line)
were included in every set of experiments. The description of
the CGH copy number changes followed the guidelines
suggested by the ISCN (1995) [25].
Cytogenetic Complexity and Survival
To access the prognostic impact of the cytogenetic profile
in UPTs, the cases for which survival information was
available were divided in two groups — those with a simple
karyotype (up to five changes), and the rest with massive
aberrations (18–51 changes). The survival of patients was
estimated from the time of diagnosis, using Kaplan-Meier
analysis and log-rank test. P values less than 0.05 were
accepted as statistically significant.
Results
Chromosome Banding
The cytogenetic analysis was successful in 18 of the
cases, whereas no mitoses were found in the remaining two
cases (Table 2). Abnormal karyotypes (Figures 3 and 4)
were identified in 17 tumors, whereas only normal meta-
phases were found in a single tumor sample. The tumor
karyotypes displayed a variety of chromosomal abnormal-
ities, with the vast majority being unbalanced changes. The
number of chromosomal aberrations detected per tumor
Figure 3. A G-banding karyogram from case 13 showing, among other
aberrations, the rearranged chromosomes 21 and 22, which established an
Ewing sarcoma diagnosis. See Table 2 for a detailed description of the tumor
karyotype.
Figure 4. A G-banding karyogram from case 1 showing a representative
adenocarcinoma karyotype with multiple complex chromosome aberrations.
See Table 2 for a detailed description of the tumor karyotype.
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ranged from 1 to 51 changes (Table 2), whereas in total, 54
different breakpoints were involved in structural aberrations.
Twenty breakpoints were observed recurrently. Band 6q15
was involved in aberrations at the highest frequency ( in 30%
of the cases) followed by 3p13 and 7q22 (both in 20% of
the cases) (Figure 1). Gains and losses of entire copies or
chromosomal parts were detected all along the chromo-
somes (Figure 2). The most frequent losses were those of
6q23 ( in 57% of the cases), 11q14–11q24 ( in 50%), and
6q21–22 ( in 46%), whereas the most frequent gain was that
of 7q22 ( in 29% of the cases).
Interphase FISH
IgH rearrangements (Figure 5) were found in four of five
samples examined, with one of them also displaying ALK
rearrangements. The percentage of cells with breakapart
signals was highly elevated in three of the examined cases
(cases 5, 10, and 16), reaching the values of 71.6%, 58.4%,
and 66.6%, respectively, in the analyzed cell population. In
the control preparations, the percentages of nuclei with IgH
and ALK breakapart signals were 4.9 and 0, respectively.
The results of the interphase FISH analysis using the IgH
and ALK probes in five malignant neoplasms are presented
in Table 2.
CGH
The CGH analysis of 11 tumor samples revealed DNA
copy number changes in seven cases, whereas in the
remaining four no imbalances were detected (Table 2). The
DNA copy number changes identified per tumor sample
ranged from 2 to 46 changes. Imbalances at 12 chromosome
regions were observed recurrently. The most common were
gains of 1q21 and 11p12–15, both detected in one third of
the cases. Furthermore, the latter imbalances showed
values that not only exceeded the thresholds but also
reached the 99% confidence interval.
Cytogenetic Complexity and Patients’ Survival
The group of patients with tumors displaying complex
karyotypes appeared to have a median survival time of 3
months, whereas the group of patients with tumors having
simple chromosomal changes showed a median survival
time of 19.7 months. The observed difference in survival time
between the two groups of patients (Figure 6) was statisti-
cally significant (P=0.003).
Discussion
In this study, the identification of well -established cytoge-
netic markers was sufficient to provide a definitive diagnosis
for five of the examined UPT cases, thus distinguishing them
from the metastatic neoplasms of unknown primary site.
Although no evidence of lymphoma-associated changes
was found in the G-banding analysis, based solely on the
cycling tumor cell populations, the detection of IgH rear-
rangements by interphase FISH (Figure 5) confirmed the
lymphoma diagnosis [27] in four cases (cases 5, 10, 16, and
17). Among other karyotypic changes in the fifth case (case
13), the finding of derivative chromosomes 21 and 22 —
rearranged in bands q22 and q12, respectively (Figure 3) —
established an Ewing sarcoma diagnosis [11]. The molec-
ular genetic detection of EWS /ERG fusion gene expression
by RT-PCR (data not shown) unambiguously confirmed the
diagnosis of Ewing sarcoma. The present findings demon-
strate that combined interphase and metaphase cytogenetic
analysis can be an adjunct to the diagnostic procedure in a
subset of UPTs without clear morphological features that
appear either as anaplastic large cell lymphomas or small
cell round cell tumors, in which the conventional histological
methods are not always capable of providing the accurate
diagnosis.
The pattern of chromosomal changes in the remaining
15 tumors — although in some cases pointing toward a
tentative tumor origin — does not contribute to the recog-
nition of the definitive primary site. Several imbalances
detected in the karyotypes have been previously recognized
as ‘‘specific’’ or ‘‘most frequent’’ for several diagnostic
entities [28,29]. In case 1, for example, the finding of losses
of 9p and 18q as well as a gain of 20q points to a pancreatic
origin because the latter imbalances are among the top
10 in pancreatic cancers previously investigated, whereas
Figure 6. Kaplan -Meier survival curves for the two groups of patients — one
with tumors displaying 1 to 5 changes ( solid line ), and the other with tumors
having 18 to 51 changes ( square dot line ). The difference in survival time
between the two groups was statistically significant (P=0.003 ).
Figure 5. IgH breakapart signals in interphase nuclei from case 16,
demonstrating IgH rearrangements.
28 Cytogenetic Profile of Unknown Primary Tumors Pantou et al.
Neoplasia . Vol. 5, No. 1, 2003
another pattern of imbalances— losses of 4q, 8p, 6q, and
13q and gains of 3q and 7q— detected in case 6 points
either to hepatobiliary or to lung cancer. However, because
none of the identified changes is pathognomonic, in a
complex karyotype, one cannot distinguish between aberra-
tions specifically associated with a tissue origin and those
that may promote tumor dissemination into a specific
anatomic site. Besides, all the so-called ‘‘specific’’ aberra-
tions refer to primary tumors, whereas very limited informa-
tion exists on cytogenetic aberrations that differentiate a
metastasis from its primary counterpart. The application of
techniques that allow the use of archival metastatic samples
can speed up the accumulation of the large-scale profiling
needed before a cytogenetic algorithm can be used as a
valuable tool to suggest the site at which each tumor has
arisen.
In spite of the inability to trace the origin in 15 of the
investigated UPTs, G-banding and CGH data obtained
in the present study provide information for the patho-
genesis of UPTs, outlining their genetic makeup for the first
time. The cytogenetic profile based solely on G-banding
findings was characterized by numerous and complex,
mostly unbalanced, chromosome aberrations (Figure 4),
with an average of 11 chromosome changes per case. The
discrepancies observed between G-banding and CGH
findings in some of the cases (Table 2) might represent
either noncycling tumor cell populations, which can be
detected by CGH but not by G-banding (e.g., case 9), or,
alternatively, the existence of more than one cytogeneti-
cally related clones (e.g., cases 1 and 6) or even unrelated
clones (e.g., case 11). Despite the discrepancies, how-
ever, the combinational methodological approach revealed
chromosome imbalances in two more cases (not informa-
tive by G-banding analysis) as well as additional gains and
losses in some other cases (Table 2). Thus, the average
DNA copy number changes per tumor increased to 15.
Furthermore, when CGH data were normalized for ploidy
on the basis of cytogenetically detected triploid clones, by
setting the threshold values at 1.17 and 0.83, the average
DNA copy number changes per tumor increased to 22.6.
Therefore, the values identified in the present series of
unknown primary cancers are undoubtedly higher com-
pared to those reported for organ-specific carcinomas
included in other series [30,31] (e.g., 5 to 6 in colorectal,
bladder, and renal carcinomas; 6 to 8 in breast, endome-
trial, ovarian, and prostate cancers; 8 to 10 in pancreatic,
gastro-esophageal, cervical, and lung cancers), providing
genotypic evidence of the highly aggressive phenotype of
this tumor entity.
The pattern of chromosomal changes identified in the
present series of tumors indicates that, groupwise, UPTs
are characterized by massive genome alterations compa-
rable to other distal metastases investigated with the same
techniques [32–35]. Considering, however, the genomic
profile of each individual case, it becomes also apparent
that a single tumor showed no imbalances and some
tumors displayed only a few changes, even after combining
the cytogenetic and CGH data. In contrast to the case
without abnormalities, which we consider cytogenetically
not informative and representing most likely stromal cell
contamination, the finding of tumors that carry few aberra-
tions may well be particularly interesting. Evidence that
tumor progression may proceed without a concomitant
increase in karyotypic complexity has been provided also by
previous reports of metastatic lesions with only simple
chromosome abnormalities [32–34]. Thus, the finding of
few aberrations in a tumor subset of the present series may
suggest that the development and the metastatic capacity
of UPTs— theoretically acquired early in tumor develop-
ment because no primary lesion is detectable — are not
merely the result of an accumulation of chromosomal
events. There might also be other, functionally different
mechanisms that drive the cells to the acquisition of a
metastatic phenotype early in tumor development and to
potential for ‘‘homing’’ in different organs. The unexpected
low frequency of p53 mutations found by other groups
[13,14] in metastases of unknown primary, compared to
what would have been predicted if UPT pathogenesis was
similar to that of common primary cancers, provides
another line of evidence supporting that these tumors differ
pathogenetically from other metastases of specified tumor
tissue origin. However, although cytogenetic complexity
does not seem to be a prerequisite for UPTs development,
the data suggest that the presence of massive genomic
changes in a tumor (Figure 4) is significantly associated
with a poor prognosis (Figure 6). The median survival time
of 3 months in patients with tumors displaying a complex
karyotype was significantly (P=0.003) shorter than the
respective median of 19.7 months in patients with tumors
having few chromosomal changes. If the cytogenetic profile
is established as a prognostic factor in UPTs, it could be
used to identify subgroups of patients with more or less
favorable prognosis and/or treatable disease, even in
cases where the nature of the primary tumor is never
identified.
Although the chromosome regions involved in aberrations
in the present series of UPTs were extended along the
whole genome, several bands appear to be nonrandom
(Figure 1). Furthermore, three peaks were observed at
6q15, 3p13, and 7q22 bands, which showed the highest
frequencies in the total series of cytogenetically examined
tumors. It is of interest that two of these bands, 3p13 and
7q22, were among the imbalances found in the only three
metastases of unknown origin previously investigated by
CGH [22]. In addition, gains of 1q21 and 7q22, which were
among the most common chromosome imbalances iden-
tified on the basis of the combined G-banding and CGH
data in the present series (Figure 2), were overrepresented
also in the three metastases of unknown origin previously
reported. As those metastases were located in the brain
whereas most of the present tumors were skeletal meta-
stases, one can assume that the above chromosome regions
might be associated with the acquisition of the unique
metastatic potential of UPTs rather than the site of meta-
stasis or the tumor site specificity. Moreover, the over-
representation of 1q21, which has also been identified in
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metastases at different sites and of various tissue origins
[36], further supports that this chromosome band might
harbor genes of importance for the acquisition of the meta-
static potential of a tumor.
When the findings of chromosome aberrations were con-
sidered separately for each histologic subgroup (Figure 1), a
preferential involvement of 4q31, 6q15, 10q25, and 13q22
was revealed in adenocarcinomas, whereas involvement of
11q22 was found in the rest of the carcinomas. Besides, on
the basis of cytogenetic findings, adenocarcinomas showed
the highest number of aberrations per tumor, with an average
of 16 compared to three changes per tumor in the rest of the
carcinomas. Whether the accumulation of data on genome-
wide alterations in UPTs will prove the observed quantitative
and also qualitative genetic differences between carcinomas
with and without adenocarcinoma features, which constitute
almost 90% of all metastatic cancers with unknown primary
site, remains to be further clarified. Recent survival data on a
large series of UPT patients [9,37], however, provide an
indirect support to the above hypothesis because a non-
adenocarcinoma histology was among the features that
characterized the subgroup of patients with the longest
survival. The difference between adenocarcinomas and
carcinomas in the overexpression of Her-2 oncogene, which
has also been reported in a series of cancers of unknown
primary site [38], further supports the assumption that
genotypic differences do exist between the two histologic
subgroups.
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